

Novel Approaches to Treat and/or Prevent Progression of Chronic Inflammatory Skin Conditions With a Long Duration of Efficacy



A global fortune 500 company is **seeking research and technologies related to the treatment or prevention of chronic inflammatory skin conditions (e.g. atopic and allergic dermatitis)**. Research should relate to **therapeutic or preventative interventions to modulate disease severity/ progression. The intervention should achieve an extended duration of efficacy with a single/ short administration window**. Treatments should reduce inflammation or pruritus for at least 6 months. Our client is particularly interested in validated research ready for further development (e.g., manufacturing, or clinical testing). The research should have a path for exclusivity (patents, etc.) and should have freedom to operate in the field.

Approaches of Interest:

- Any therapeutic approach which can achieve long duration of modulated disease progression or severity. This includes, but is not limited to: allogeneic cell-based therapies, gene therapies/gene silencing/gene vaccination, vaccines and other immunotherapies, immunomodulation, monoclonal antibody half-life extension, T-cell modulating therapies
- Approaches should be minimally invasive; single/minimal number of treatment administrations are preferred
- Research with validation in laboratory animal models is of interest if it has the potential to be applied to dermatitis in higher order species
- Any treatment platforms from other disease areas (e.g. asthma) that have potential to be applied to pruritus and inflammation associated with chronic inflammatory skin conditions are also of interest
- Approaches and procedures that have reproducible methods to obtain and grow appropriate cell

Out of Scope:

- Allergen specific desensitisation
- New formulation of known small molecules or monoclonal antibodies

Developmental Stages of Interest:

- Opportunities at basic research phase to clinical phase III are within scope, with a preference for later stage research with validation data in higher species
- Opportunities with *in vivo* validation are preferred, although opportunities with *in vitro* validation will still be considered

Submission Information and Opportunity for Collaboration:

Submission of one-page briefs are encouraged, with any optional supplementary information e.g. publications. Intellectual property status of the research should be included where relevant. Identified risks and mitigation plans for the proposed approach are highly valued. In submitting to this campaign, you confirm that your submission contains only non-confidential information. This **submission form** may be used to outline novel projects proposals, or to supplement other submissions.

Our client is open to a range of outcomes, with the most appropriate path determined on a case by case basis dependent on the quality and needs of the submission. Example outcomes include licensing of assets, partnering on research, development, and/or manufacture of a treatment, research collaborations and project funding.

Opportunities sought

- 💡 Technologies
- 🎓 Academics and expertise
- 🧪 Research projects
- 🏆 Centres of excellence
- 🏢 Spinout companies
- 🧬 Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **23rd October 2023 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

